Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.

Browsing by Subject "Oral bioavailability"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Development of Amorphous Solid Dispersion Tablet of Sorafenib with Improved Oral Bioavailability
    (2021-05) Song, Sichen
    An amorphous solid dispersion (ASD) immediate release tablet of sorafenib (SOR) was developed to improve oral bioavailability. The ASD was produced by coprecipitating both SOR and an enteric polymer, hydroxypropyl methylcellulose acetate succinate (HPMC-AS). The goal of maintaining supersaturation of ASDs was used to guide the selection of drug loading and HPMC-AS grade. The ASD of 40% drug loading with HPMC-AS M grade, which exhibits superior physical stability, enhanced dissolution extent and moderate hygroscopicity, was selected for further tablet development. Tablet formulation composition and dry granulation process were designed to achieve fast disintegration and adequate flow properties, and to mitigate over-granulation that would compromise in vivo performance. A material sparing and expedited approach was used to optimize compaction pressure to manufacture the ASD tablet with low friability and rapid disintegration. The resulting SOR ASD tablet showed enhanced in vitro dissolution rate and extent compared to the marketed product Nexavar®. A pharmacokinetic study in dogs suggested that the SOR ASD tablet exhibited a 1.5-fold improvement in the relative oral bioavailability compared to Nexavar®.